Patients with CML, unlike patients with acute lymphoblastic leukemia, are likely to have a longer life expectancy with and without treatment. Those with CML can still have a life expectancy of 3 to 5 ...

Researchers evaluated long-term outcomes among patients with CML living in LMICs who received imatinib through financial assistance from the Max Foundation.

A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.

Cortes discussed the evolution of chronic myeloid leukemia treatment and emerging strategies aimed at improving outcomes and quality of life. Dr. Jorge E. Cortes sat down with CURE to discuss the ...

Terns Pharmaceuticals Inc. (NASDAQ:TERN) is among the hottest SMID-cap stocks so far in 2025. On November 17, Evan Seigerman ...

In this video, Christine McMahon, MD, discusses the results of the phase 3 ASC4FIRST study, pertaining to chronic myelogenous leukemia, presented at ASCO Annual Meeting. McMahon, an assistant ...

It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...

The latest research on chronic myeloid leukemia (CML) presented at the 2024 American Society of Hematology 2024 Annual Meeting and Exposition is reported by Dr Jorge Cortes from Georgia Cancer Center ...

After being diagnosed with chronic myeloid leukemia, graphic designer Aaron von Freter was able to participate in a clinical trial that offered him hope of being cured. When Aaron von Freter learned ...

Chronic myeloid leukemia (CML) is a hematological tumor marked by the bcr-abl fusion gene formed by t (9;22) (q34;q11), which translated into the BCR-ABL protein. Tyrosine kinase inhibitors (TKIs) ...